drugset
drugset / Trial / NCT03472352

Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Solid Tumors

NCT03472352 ↗

Phase 1 Unknown 15 enrolled Hangzhou Converd Co., Ltd. The Second People's Hospital of Yibin · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label study to evaluate the safety and efficacy of an anticancer medication (A01) with immune cells (IC01) in subjects with advanced solid tumors.

Timeline

Start
2018-04
Primary completion
2019-04
Completion
2019-04

Drugs

EvaluationDrugModalityDoseRoute
Subject A01 Unknown — —
Subject IC01 Cell therapy — —

Indications

cancer